Effects of the Omicron variant of coronavirus disease 2019 on anaemia treatment for patients undergoing peritoneal dialysis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Blackwell Science Country of Publication: Australia NLM ID: 9615568 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1440-1797 (Electronic) Linking ISSN: 13205358 NLM ISO Abbreviation: Nephrology (Carlton) Subsets: MEDLINE
    • Publication Information:
      Original Publication: Carlton, Vic., Australia : Blackwell Science,
    • Subject Terms:
      COVID-19* ; Anemia*/diagnosis ; Anemia*/drug therapy ; Anemia*/etiology ; Peritoneal Dialysis*/adverse effects ; Erythropoietin*/therapeutic use ; Erythropoietin*/metabolism; Humans ; Renal Dialysis/adverse effects ; Hemoglobins/metabolism ; Retrospective Studies ; Ferritins ; Registries ; SARS-CoV-2 ; Isoquinolines
    • Abstract:
      Aim: Patients undergoing dialysis are at high risk for coronavirus disease 2019 (COVID-19). Haemoglobin (Hb) levels may be changed in patients infected with the Omicron variant of COVID-19 who are undergoing peritoneal dialysis (PD). Therefore, we aimed to explore the effect of anti-anaemia treatment on such patients.
      Methods: This study enrolled patients undergoing PD who were infected with the Omicron variant of COVID-19 at our centre between November 2022 and February 2023. We retrospectively analysed changes in Hb levels and explored the effectiveness of roxadustat and recombinant human erythropoietin (rhEPO) for patients infected with the Omicron variant of COVID-19.
      Results: Among 125 enrolled patients, 83 (66.4%) were infected with the Omicron variant and 75 (90.4%) patients mainly experienced mild or moderate disease. During infection, C-reactive protein (CRP) levels were higher than those before infection (p < .001). Additionally, their CRP levels were negatively correlated with Hb levels (p = .002). However, Hb levels were decreased 1 month after infection (109.61 ± 10.64 g/L vs. 115.69 ± 12.04 g/L; p < .001). The roxadustat treatment group did not exhibit significantly decreased Hb levels 1 month after infection (114.57 ± 14.11 vs. 117.51 ± 10.74 g/L; p = .225). Conversely, the rhEPO treatment group experienced a mild decrease in Hb levels (108.69 ± 11.20 vs. 115.03 ± 12.23 g/L; p = .001). Ferritin levels increased in both groups during infection (p = .495). Two months after infection, ferritin levels (median, 205.0 ng/mL) were significantly decreased compared with during infection (median, 377.4 ng/mL) (p < .001) in the roxadustat treatment group.
      Conclusion: Roxadustat was effective than rhEPO for treating anaemia in patients undergoing PD who were infected with the Omicron variant of COVID-19.
      (© 2024 Asian Pacific Society of Nephrology.)
    • References:
      Lu G, Ling Y, Jiang M, et al. Primary assessment of the diversity of Omicron sublineages and the epidemiologic features of autumn/winter 2022 COVID-19 wave in Chinese mainland. Front Med. 2023;31:1-10. doi:10.1007/s11684-022-0981-7.
      Yavuz D, Karagöz Özen DS, Demirağ MD. COVID-19: mortality rates of patients on hemodialysis and peritoneal dialysis. Int Urol Nephrol. 2022;54:2713-2718. doi:10.1007/s11255-022-03193-6.
      Palladino M. Complete blood count alterations in COVID-19 patients: a narrative review. Biochem Med (Zagreb). 2021;31:030501. doi:10.11613/BM.2021.030501.
      Taneri PE, Gómez-Ochoa SA, Llanaj E, Raguindin PE, Rojas LZ, et al. Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis. Eur J Epidemiol. 2020;35:763-773. doi:10.1007/s10654-020-00678-5.
      Takkavatakarn K, Thammathiwat T, Phannajit J, et al. The impacts of hypoxia-inducible factor stabilizers on laboratory parameters and clinical outcomes in chronic kidney disease patients with renal anemia: a systematic review and meta-analysis. Clin Kidney J. 2023;16:845-858. doi:10.1093/ckj/sfac271.
      Yang W, Israni RK, Brunelli SM, Joffe MM, Fishbane S, Feldman HI. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol. 2007;18:3164-3170. doi:10.1681/ASN.2007010058.
      Vlagopoulos PT, Tighiouart H, Weiner DE, et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol. 2005;16:3403-3410. doi:10.1681/ASN.2005030226.
      Hou YP, Mao XY, Wang C, et al. Roxadustat treatment for anemia in peritoneal dialysis patients: a randomized controlled trial. J Formos Med Assoc. 2022;121:529-538. doi:10.1016/j.jfma.2021.06.004.
      Joharapurkar AA, Pandya VB, Patel VJ, Desai RC, Jain MR. Prolyl hydroxylase inhibitors: a breakthrough in the therapy of anemia associated with chronic diseases. J Med Chem. 2018;61:6964-6982. doi:10.1021/acs.jmedchem.7b01686.
      Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis. 2020;71:2027-2034. doi:10.1093/cid/ciaa344.
      Htay H, Foo MWY, Jayaballa M, et al. Clinical features, management and outcomes of peritoneal dialysis patients during Delta and Omicron waves of COVID-19 infections. Int Urol Nephrol. 2023;55:2075-2081. doi:10.1007/s11255-023-03496-2.
      Chow KM, Chan JYH, Wong SSH, et al. Impact of COVID-19 on the mortality of dialysis patients and kidney transplant recipients during the Omicron fifth wave in Hong Kong. Hong Kong Med J. 2023;29:82-83. doi:10.12809/hkmj2210309.
      Huang YH, Tu MQ, Wang SP, et al. Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: a retrospective single center analysis. Travel Med Infect Dis. 2020;36:101606. doi:10.1016/j.tmaid.2020.101606.
      Wang L, Duan Y, Zhang W, et al. Epidemiologic and clinical characteristics of 26 cases of COVID-19 arising from patient-to-patient transmission in Liaocheng, China. Clin Epidemiol. 2020;12:387-391. doi:10.2147/CLEP.S249903.
      Zhao L, Liu H. Inflammatory status and its impact on renal anemia treatment in chronic kidney disease patients. Chin J Blood Purif. 2020;19:149-152. doi:10.3390/nu14102116.
      McCarthy JT, El-Azhary RA, Patzelt MT, Weaver AL, Albright RC, et al. Survival, risk factors, and effect of treatment in 101 patients with calciphylaxis. Mayo Clin Proc. 2016;91:1384-1394. doi:10.1016/j.mayocp.2016.06.025.
      Ganz T. Anemia of inflammation. N Engl J Med. 2019;381:1148-1157.
      Ashby DR, Gale DP, Busbridge M, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009;75:976-981. doi:10.1038/ki.2009.21.
      Elahi S. Hematopoietic responses to SARS-CoV-2 infection. Cell Mol Life Sci. 2022;79:187. doi:10.1007/s00018-022-04220-6.
      Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019;381:1011-1022. doi:10.1056/NEJMoa1901713.
      Akizawa T, Otsuka T, Reusch M, Ueno M. Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: a randomized, phase 3, multicenter, open-label study. Ther Apher Dial. 2020;24:115-125. doi:10.1111/1744-9987.12888.
      Bao L, Bian X, Zhang A, Huang J, Ren L, Luo C. Long-term efficacy, safety, and medication compliance of roxadustat on peritoneal dialysis patients with renal anemia affected by the COVID-19 pandemic: a retrospective study. Ann Palliat Med. 2022;11:2017-2024. doi:10.21037/apm-22-555.
      Thomas MR, Scully M. Clinical features of thrombosis and bleeding in COVID-19. Blood. 2022;140:184-195. doi:10.1182/blood.2021012247.
      Treml B, Wallner B, Blank C, Fries D, Schobersberger W. The influence of environmental hypoxia on hemostasis-a systematic review. Front Cardiovasc Med. 2022;9:813550. doi:10.3389/fcvm.2022.813550.
      Wang Y, Huang X, Yang W, Zeng Q. Platelets and high-altitude exposure: a meta-analysis. High Alt Med Biol. 2022;23:43-56. doi:10.1089/ham.2021.0075.
      Wen W, Cai S, Li Y, Wu X. Risk factors and prognosis for coronavirus disease 2019 among 131 hemodialysis patients during the Omicron variant epidemic. Ren Fail. 2023;45:2228924. doi:10.1080/0886022X.2023.2228924.
    • Grant Information:
      YN2021ZD01 Peking University International Hospital Research Funds
    • Contributed Indexing:
      Keywords: Omicron; anaemia; coronavirus disease 2019; peritoneal dialysis; roxadustat
    • Accession Number:
      0 (Hemoglobins)
      9007-73-2 (Ferritins)
      11096-26-7 (Erythropoietin)
      0 (Isoquinolines)
    • Subject Terms:
      SARS-CoV-2 variants
    • Publication Date:
      Date Created: 20240221 Date Completed: 20240319 Latest Revision: 20240319
    • Publication Date:
      20240319
    • Accession Number:
      10.1111/nep.14274
    • Accession Number:
      38382901